RPRX - Royalty Pharma PLC Stock Price, Fair Value and News

27.60USD+0.14 (+0.51%)Market Closed

Market Summary

USD27.60+0.14

Market Closed

0.51%

RPRX Stock Price

View Fullscreen

RPRX RSI Chart

RPRX Valuation

Market Cap

12.4B

Price/Earnings (Trailing)

10.89

Price/Sales (Trailing)

5.25

EV/EBITDA

9.54

Price/Free Cashflow

4.13

RPRX Price/Sales (Trailing)

RPRX Profitability

EBT Margin

72.20%

Return on Equity

11.25%

Return on Assets

6.93%

Free Cashflow Yield

24.19%

RPRX Fundamentals

RPRX Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

5.36%

Rev. Growth (Qtr)

11.14%

RPRX Earnings

Earnings (TTM)

1.1B

Earnings Growth (Yr)

208.39%

Earnings Growth (Qtr)

585.5%

Breaking Down RPRX Revenue

Last 7 days

-6.3%

Last 30 days

-8.1%

Last 90 days

-1.6%

Trailing 12 Months

-23.1%

How does RPRX drawdown profile look like?

RPRX Financial Health

Current Ratio

7.9

Debt/Equity

0.61

Debt/Cashflow

0.49

RPRX Investor Care

Dividend Yield

2.9%

Dividend/Share (TTM)

0.8

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

2.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.4B	2.4B	2.3B	2.4B
2022	2.3B	2.3B	2.2B	2.2B
2021	2.4B	2.4B	2.5B	2.3B
2020	1.2B	1.6B	1.6B	1.9B
2019	1.2B	1.4B	1.6B	1.8B
2018	0	0	0	983.2M
2017	0	0	0	877.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Royalty Pharma PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	bassler bonnie l	acquired	37,483	30.2283	1,240	-
Mar 28, 2024	fernandez henry a	acquired	37,483	30.2283	1,240	-
Feb 20, 2024	riggs rory b	acquired	-	-	300,000	-
Jan 04, 2024	riggs rory b	sold	-983,504	27.5476	-35,702	-
Jan 03, 2024	riggs rory b	sold	-5,532,280	27.7867	-199,098	-
Jan 02, 2024	riggs rory b	sold	-6,707,080	28.5165	-235,200	-
Dec 29, 2023	bassler bonnie l	acquired	37,493	27.711	1,353	-
Dec 29, 2023	avara management ltd	sold	-1,845,410	28.0444	-65,803	-
Dec 29, 2023	fernandez henry a	acquired	37,493	27.711	1,353	-
Dec 28, 2023	avara management ltd	sold	-5,918,930	28.2038	-209,863	-

Which funds bought or sold RPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	OneAscent Financial Services LLC	reduced	-1.69	15,000	246,000	0.03%
Apr 16, 2024	Overbrook Management Corp	reduced	-4.7	187,202	6,357,930	1.71%
Apr 16, 2024	Robbins Farley	unchanged	-	46.00	608	-%
Apr 16, 2024	MCF Advisors LLC	new	-	10,326	10,326	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	new	-	218,584	218,584	-%
Apr 15, 2024	PFS Partners, LLC	sold off	-100	-5,797	-	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	21.00	274	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	23.00	304	-%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	added	41.67	126	1,549	-%
Apr 11, 2024	Gulf International Bank (UK) Ltd	unchanged	-	71,000	955,000	0.02%

Are Funds Buying or Selling RPRX?

Are funds buying RPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPRX

No. of Funds

Unveiling Royalty Pharma PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.54%	37,997,522	SC 13G/A
Feb 13, 2024	general atlantic, l.p.	5.6%	26,259,141	SC 13G/A
Feb 09, 2024	morgan stanley	9.2%	41,159,749	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 13, 2023	general atlantic, l.p.	5.6%	26,244,741	SC 13G/A
Feb 10, 2023	morgan stanley	9.9%	43,775,398	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	1.59%	7e+06	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.08%	35,627,791	SC 13G/A
Oct 04, 2022	giuliani mario germano	2.7%	11,604,660	SC 13D/A

Recent SEC filings of Royalty Pharma PLC

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Feb 28, 2024	144	Notice of Insider Sale Intent
Feb 22, 2024	4	Insider Trading
Feb 15, 2024	8-K	Current Report
Feb 15, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Royalty Pharma PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Royalty Pharma PLC News

Latest updates

Royalty Pharma PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	11.1%	596	536	538	684	566	573	536	562	576	586	555	573	759	538	511	128	457	464	156	-	-
Costs and Expenses	-104.4%	-16.83	385	289	205	1,048	381	158	342	422	283	-189	344	258	28.00	102	139	-874	-68.22	130	-	-
S&GA Expenses	3.4%	59.00	57.00	48.00	86.00	73.00	51.00	52.00	52.00	46.00	49.00	45.00	43.00	50.00	51.00	43.00	38.00	23.00	26.00	30.00	-	-
R&D Expenses	-99.0%	1.00	51.00	1.00	1.00	51.00	26.00	1.00	101	-	91.00	3.00	3.00	8.00	5.00	6.00	8.00	16.00	23.00	21.00	-	-
EBITDA Margin	233.1%	0.80*	0.24*	0.28*	0.34*	0.19*	0.48*	0.48*	0.61*	0.61*	0.69*	0.87*	0.79*	0.96*	1.81*	1.81*	2.01*	1.50*	1.12*	1.29*	1.51*	1.83*
Interest Expenses	2.7%	47.00	46.00	47.00	47.00	47.00	47.00	47.00	47.00	47.00	44.00	37.00	37.00	38.00	31.00	34.00	54.00	63.00	69.00	69.00	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	487.8%	718	122	351	509	-610	220	492	128	54.00	222	807	159	367	624	602	109	1,447	440	179	-	-
EBT Margin	350.6%	0.72*	0.16*	0.20*	0.26*	0.10*	0.40*	0.40*	0.53*	0.54*	0.63*	0.81*	0.74*	0.88*	1.70*	1.66*	1.80*	1.36*	0.94*	1.09*	1.27*	1.54*
Net Income	585.5%	494	72.00	228	341	-456	143	305	52.00	8.00	102	441	69.00	171	582	442	38.00	1,420	409	152	-	-
Net Income Margin	507.5%	0.48*	0.08*	0.11*	0.14*	0.02*	0.23*	0.21*	0.26*	0.27*	0.45*	0.41*	0.42*	0.50*	1.16*	1.48*	1.67*	1.29*	0.86*	0.98*	1.16*	1.40*
Free Cashflow	34.7%	773	574	608	1,034	570	539	575	460	490	470	532	526	566	509	489	471	478	419	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	3.3%	16,382	15,856	17,121	17,074	16,813	17,673	17,740	17,379	17,516	17,732	16,515	15,914	16,020	15,991	15,686	14,068	12,450	11,370
Current Assets	-26.3%	1,274	1,729	2,954	2,631	2,555	2,342	3,504	2,982	2,878	2,776	2,707	2,416	2,697	2,784	3,391	-	832	2,609
Cash Equivalents	-49.1%	477	936	2,173	1,976	1,711	992	2,108	1,792	1,541	1,801	1,142	709	1,009	1,553	2,322	498	246	1,924
Liabilities	0.4%	6,298	6,270	7,308	7,252	7,288	7,256	7,332	7,237	7,267	7,346	6,110	6,077	6,124	6,192	6,291	6,300	6,308	6,818
Current Liabilities	26.1%	161	128	1,172	1,117	1,167	1,132	182	136	171	255	284	256	308	270	451	-	333	580
Long Term Debt	0.1%	6,135	6,131	6,127	6,123	6,119	6,115	7,106	7,101	7,096	7,091	5,826	5,821	5,817	5,812	5,730	-	5,956	6,238
LT Debt, Current	-	-	-	999	998	998	997	-	-	-	-	-	-	-	-	182	-	282	281
LT Debt, Non Current	0.1%	6,135	6,131	6,127	6,123	6,119	6,115	7,106	7,101	7,096	7,091	5,826	5,821	5,817	5,812	5,730	-	5,956	6,238
Shareholder's Equity	5.2%	10,084	9,585	9,814	9,822	9,525	10,416	10,408	10,142	10,249	10,387	10,405	9,837	9,896	9,799	9,395	7,163	6,141	4,552
Retained Earnings	17.9%	2,518	2,135	2,253	2,217	1,965	2,505	2,446	2,225	2,255	2,321	2,292	1,924	1,921	1,807	1,571	-	2,825	1,216
Additional Paid-In Capital	0.1%	4,011	4,007	4,031	3,740	3,666	3,633	3,571	3,543	3,508	3,454	3,416	2,931	2,866	2,612	2,557	-	-	-
Shares Outstanding	-0.2%	448	448	448	446	438	437	436	434	415	409	400	390	375	370	354	-	37.00	37.00
Minority Interest	3.2%	3,558	3,446	3,532	3,868	3,897	4,264	4,381	4,364	4,472	4,594	4,672	4,955	5,077	5,347	5,238	-	36.00	64.00
Float	-	-	-	13,700	-	-	-	18,500	-	-	-	16,600	-	-	-	4,200	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	34.7%	773	574	608	1,034	570	539	575	460	490	470	532	526	566	509	489	471	478	419	-	-	-
Cashflow From Investing	-121.9%	-1,000	-450	-63.43	-558	415	-1,425	-30.18	11.00	-551	-845	126	-599	-832	-920	-244	-761	-62.82	-615	-	-	-
Cashflow From Financing	82.9%	-231	-1,359	-347	-210	-265	-230	-228	-220	-198	1,034	-224	-226	-277	-357	1,579	543	-285	-280	-	-	-
Buy Backs	-79.0%	30.00	144	134	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-	-

RPRX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total income and other revenues	$ 2,354,554	$ 2,237,215	$ 2,289,463
Operating expenses
Provision for changes in expected cash flows from financial royalty assets	560,656	904,244	452,842
Research and development funding expense	52,000	177,106	200,084
Amortization of intangible assets	0	5,670	22,996
General and administrative expenses	249,748	227,303	182,826
Financial royalty asset impairment	0	615,827	0
Total operating expenses, net	862,404	1,930,150	858,748
Operating income	1,492,150	307,065	1,430,715
Other (income)/expense
Equity in (earnings)/losses of equity method investees	(28,882)	8,973	19,490
Interest expense	187,187	187,961	166,142
Losses/(gains) on derivative financial instruments	2,290	(96,610)	21,532
(Gains)/losses on equity securities	(87,139)	33,442	48,066
(Gains)/losses on available for sale debt securities	(230,840)	6,815	(17,859)
Interest income	(72,291)	(78,335)	(53,535)
Other non-operating expense, net	21,737	14,755	5,678
Total other (income)/expense, net	(207,938)	77,001	189,514
Consolidated net income before tax	1,700,088	230,064	1,241,201
Income tax expense	0	0	0
Consolidated net income	1,700,088	230,064	1,241,201
Net income attributable to non-controlling interests	565,254	187,232	621,473
Net income attributable to Royalty Pharma plc	$ 1,134,834	$ 42,832	$ 619,728
Earnings per Class A ordinary share:
Basic (in dollars per share)	$ 2.54	$ 0.10	$ 1.49
Diluted (in dollars per share)	$ 2.53	$ 0.10	$ 1.49
Weighted average Class A ordinary shares outstanding:
Basic (in shares)	447,601	437,963	414,794
Diluted (in shares)	602,900	437,972	414,802
Income from financial royalty assets
Total income and other revenues	$ 2,197,754	$ 2,125,096	$ 2,065,083
Revenue from intangible royalty assets
Total income and other revenues	835	37,484	171,248
Other royalty income
Total income and other revenues	$ 155,965	$ 74,635	$ 53,132

RPRX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 477,010	$ 1,710,751
Marketable securities	0	24,421
Financial royalty assets	738,438	691,319
Accrued royalty receivable	14,242	16,830
Available for sale debt securities	18,300	1,300
Other royalty income receivable	22,405	19,767
Other current assets	3,798	90,520
Total current assets	1,274,193	2,554,908
Financial royalty assets, net	14,088,655	13,493,106
Equity securities	199,487	112,348
Available for sale debt securities	437,100	226,300
Equity method investments	375,894	397,175
Other assets	6,522	29,629
Total assets	16,381,851	16,813,466
Current liabilities
Distributions payable to legacy non-controlling interests	83,155	94,803
Accounts payable and accrued expenses	15,165	7,906
Interest payable	51,682	54,162
Current portion of long-term debt	0	997,512
Other current liabilities	11,375	12,400
Total current liabilities	161,377	1,166,783
Long-term debt	6,135,285	6,118,810
Other liabilities	900	2,500
Total liabilities	6,297,562	7,288,093
Commitments and contingencies
Shareholders’ equity
Deferred shares, $0.000001 par value; issued and outstanding: 2023–384,640 and 2022–371,325	0	0
Additional paid-in capital	4,011,435	3,666,160
Retained earnings	2,517,583	1,964,689
Non-controlling interests	3,557,792	3,897,223
Treasury interests	(2,629)	(2,806)
Total shareholders’ equity	10,084,289	9,525,373
Total liabilities and shareholders’ equity	16,381,851	16,813,466
Class A Ordinary Shares
Shareholders’ equity
Common stock	45	44
Class B Ordinary Shares
Shareholders’ equity
Common stock	0	0
Class R Redeemable Shares
Shareholders’ equity
Common stock	$ 63	$ 63

About Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO	Mr. Pablo Gerardo Legorreta
WEBSITE	royaltypharma.com
INDUSTRY	Biotechnology

Royalty Pharma PLC Frequently Asked Questions

What is the ticker symbol for Royalty Pharma PLC? What does RPRX stand for in stocks?

RPRX is the stock ticker symbol of Royalty Pharma PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Royalty Pharma PLC (RPRX)?

As of Wed Apr 17 2024, market cap of Royalty Pharma PLC is 12.35 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers.

What is the fair value of RPRX stock?

You can check RPRX's fair value in chart for subscribers. The fair value of Royalty Pharma PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Royalty Pharma PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Royalty Pharma PLC a good stock to buy?

The fair value guage provides a quick view whether RPRX is over valued or under valued. Whether Royalty Pharma PLC is cheap or expensive depends on the assumptions which impact Royalty Pharma PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPRX.

What is Royalty Pharma PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, RPRX's PE ratio (Price to Earnings) is 10.89 and Price to Sales (PS) ratio is 5.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPRX PE ratio will change depending on the future growth rate expectations of investors.